Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) × ceritinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 13 Lung Neoplasms 5 Adenocarcinoma of Lung 4 Neoplasms 2 Brain Neoplasms 2 Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 1 Rhabdomyosarcoma 1 Pancreatic Neoplasms 1 Neuroblastoma 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 Glioblastoma 1 ALK-positive NSCLC 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01634763 2020-12-19

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Novartis

Phase 1 Completed

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡